14 results on '"Chartier, Loic"'
Search Results
2. A tumor volume and performance status model to predict outcome before treatment in diffuse large B-cell lymphoma
- Author
-
Thieblemont, Catherine, Chartier, Loic, Dührsen, Ulrich, Vitolo, Umberto, Barrington, Sally F., Zaucha, Jan M., Vercellino, Laetitia, Gomes Silva, Maria, Patrocinio-Carvalho, Ines, Decazes, Pierre, Viailly, Pierre-Julien, Tilly, Herve, Berriolo-Riedinger, Alina, Casasnovas, Oliver, Hüttmann, Andreas, Ilyas, Hajira, Mikhaeel, N. George, Dunn, Joel, Cottereau, Anne-Ségolène, Schmitz, Christine, Kostakoglu, Lale, Paulson, Joseph N., Nielsen, Tina, and Meignan, Michael
- Abstract
Aggressive large B-cell lymphoma (LBCL) has variable outcomes. Current prognostic tools use factors for risk stratification that inadequately identify patients at high risk of refractory disease or relapse before initial treatment. A model associating 2 risk factors, total metabolic tumor volume (TMTV) >220 cm3 (determined by fluorine-18 fluorodeoxyglucose positron emission tomography coupled with computed tomography) and performance status (PS) ≥2, identified as prognostic in 301 older patients in the REMARC trial (#NCT01122472), was validated in 2174 patients of all ages treated in 2 clinical trials, PETAL (Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas; N = 510) and GOYA (N = 1315), and in real-world clinics (N = 349) across Europe and the United States. Three risk categories, low (no factors), intermediate (1 risk factor), and high (2 risk factors), significantly discriminated outcome in most of the series. Patients with 2 risk factors had worse outcomes than patients with no risk factors in the PETAL, GOYA, and real-world series. Patients with intermediate risk also had significantly worse outcomes than patients with no risk factors. The TMTV/Eastern Cooperative Oncology Group-PS combination outperformed the International Prognostic Index with a positive C-index for progression-free survival and overall survival in most series. The combination of high TMTV > 220 cm3 and ECOG-PS ≥ 2 is a simple clinical model to identify aggressive LBCL risk categories before treatment. This combination addresses the unmet need to better predict before treatment initiation for aggressive LBCL the patients likely to benefit the most or not at all from therapy.
- Published
- 2022
- Full Text
- View/download PDF
3. A tumor volume and performance status model to predict outcome before treatment in diffuse large B-cell lymphoma
- Author
-
Thieblemont, Catherine, Chartier, Loic, Dührsen, Ulrich, Vitolo, Umberto, Barrington, Sally F., Zaucha, Jan M., Vercellino, Laetitia, Gomes Silva, Maria, Patrocinio-Carvalho, Ines, Decazes, Pierre, Viailly, Pierre-Julien, Tilly, Herve, Berriolo-Riedinger, Alina, Casasnovas, Oliver, Hüttmann, Andreas, Ilyas, Hajira, Mikhaeel, N. George, Dunn, Joel, Cottereau, Anne-Ségolène, Schmitz, Christine, Kostakoglu, Lale, Paulson, Joseph N., Nielsen, Tina, and Meignan, Michael
- Abstract
•A new TMTV/ECOG-PS prognostic score was validated in 2174 patients of all ages with DLBCL treated in clinical trials and real-world series.•The combined TMTV and ECOG-PS prognostic score allows identification of patients with high-risk DLBCL before first-line treatment.
- Published
- 2022
- Full Text
- View/download PDF
4. Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA
- Author
-
Le Gouill, Steven, Ghesquières, Hervé, Oberic, Lucie, Morschhauser, Franck, Tilly, Hervé, Ribrag, Vincent, Lamy, Thierry, Thieblemont, Catherine, Maisonneuve, Hervé, Gressin, Rémy, Bouhabdallah, Krimo, Haioun, Corinne, Damaj, Gandhi, Fornecker, Luc, Bouhabdallah, Réda, Feugier, Pierre, Sibon, David, Cartron, Guillaume, Bonnet, Christophe, André, Marc, Chartier, Loic, Ruminy, Philippe, Kraeber-Bodéré, Françoise, Bodet-Milin, Caroline, Berriolo-Riedinger, Alina, Brière, Josette, Jais, Jean-Philippe, Molina, Thierry Jo, Itti, Emmanuel, and Casasnovas, René-Olivier
- Abstract
Rituximab plus polychemotherapy is the standard of care in diffuse large B-cell lymphoma (DLBCL). GAINED, a randomized phase 3 trial, compared obinutuzumab to rituximab. Transplant-eligible patients (18-60 years) with an untreated age-adjusted International Prognostic Index (aaIPI) score ≥1 DLBCL were randomized (1:1) between obinutuzumab or rituximab and stratified by aaIPI (1; 2-3) and chemotherapy regimen (doxorubicin, cyclophosphamide, prednisone plus vindesine, bleomycin [ACVBP] or vincristine [CHOP]). Consolidation treatment was determined according to response to interim positron emission tomography (PET). Responders after cycle 2 and 4 (PET2−/PET4−) received immunochemotherapy. Responders after only cycle 4 (PET2+/4−) received transplantation. The primary objective was an 8% improvement (hazard ratio [HR] = 0.73; 80% power; α risk, 2.5%; 1-sided) in 2-year event-free survival (EFS) in the obinutuzumab arm. From September 2012, 670 patients were enrolled (obinutuzumab, n = 336; rituximab, n = 334). A total of 383 (57.2%) were aaIPI 2-3, 339 (50.6%) received CHOP. Median follow-up was 38.7 months. The 2-year EFS was similar in both groups (59.8% vs 56.6%; P = .123; HR = 0.88). The 2-year PFS in the whole cohort was 83.1% (95% confidence interval, 80% to 85.8%). PET2−/4− and PET2+/4− had similar 2-year progression-free survival (PFS) and overall survival (OS): 89.9% vs 83.9% and 94.8% vs 92.8%. The 2-year PFS and OS for PET4+ patients were 62% and 83.1%. Grade 3-5 infections were more frequent in the obinutuzumab arm (21% vs 12%). Obinutuzumab is not superior to rituximab in aaIPI ≥1 DLBCL transplant-eligible patients. This trial was registered at www.clinicaltrials.gov as #NCT01659099.
- Published
- 2021
- Full Text
- View/download PDF
5. Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA
- Author
-
Le Gouill, Steven, Ghesquières, Hervé, Oberic, Lucie, Morschhauser, Franck, Tilly, Hervé, Ribrag, Vincent, Lamy, Thierry, Thieblemont, Catherine, Maisonneuve, Hervé, Gressin, Rémy, Bouhabdallah, Krimo, Haioun, Corinne, Damaj, Gandhi, Fornecker, Luc, Bouhabdallah, Réda, Feugier, Pierre, Sibon, David, Cartron, Guillaume, Bonnet, Christophe, André, Marc, Chartier, Loic, Ruminy, Philippe, Kraeber-Bodéré, Françoise, Bodet-Milin, Caroline, Berriolo-Riedinger, Alina, Brière, Josette, Jais, Jean-Philippe, Molina, Thierry Jo, Itti, Emmanuel, and Casasnovas, René-Olivier
- Abstract
Rituximab plus polychemotherapy is the standard of care in diffuse large B-cell lymphoma (DLBCL). GAINED, a randomized phase 3 trial, compared obinutuzumab to rituximab. Transplant-eligible patients (18-60 years) with an untreated age-adjusted International Prognostic Index (aaIPI) score ≥1 DLBCL were randomized (1:1) between obinutuzumab or rituximab and stratified by aaIPI (1; 2-3) and chemotherapy regimen (doxorubicin, cyclophosphamide, prednisone plus vindesine, bleomycin [ACVBP] or vincristine [CHOP]). Consolidation treatment was determined according to response to interim positron emission tomography (PET). Responders after cycle 2 and 4 (PET2−/PET4−) received immunochemotherapy. Responders after only cycle 4 (PET2+/4−) received transplantation. The primary objective was an 8% improvement (hazard ratio [HR] = 0.73; 80% power; α risk, 2.5%; 1-sided) in 2-year event-free survival (EFS) in the obinutuzumab arm. From September 2012, 670 patients were enrolled (obinutuzumab, n = 336; rituximab, n = 334). A total of 383 (57.2%) were aaIPI 2-3, 339 (50.6%) received CHOP. Median follow-up was 38.7 months. The 2-year EFS was similar in both groups (59.8% vs 56.6%; P= .123; HR = 0.88). The 2-year PFS in the whole cohort was 83.1% (95% confidence interval, 80% to 85.8%). PET2−/4−and PET2+/4−had similar 2-year progression-free survival (PFS) and overall survival (OS): 89.9% vs 83.9% and 94.8% vs 92.8%. The 2-year PFS and OS for PET4+patients were 62% and 83.1%. Grade 3-5 infections were more frequent in the obinutuzumab arm (21% vs 12%). Obinutuzumab is not superior to rituximab in aaIPI ≥1 DLBCL transplant-eligible patients. This trial was registered at www.clinicaltrials.govas #NCT01659099.
- Published
- 2021
- Full Text
- View/download PDF
6. High total metabolic tumor volume at baseline predicts survival independent of response to therapy
- Author
-
Vercellino, Laetitia, Cottereau, Anne-Segolene, Casasnovas, Olivier, Tilly, Hervé, Feugier, Pierre, Chartier, Loic, Fruchart, Christophe, Roulin, Louise, Oberic, Lucie, Pica, Gian Matteo, Ribrag, Vincent, Abraham, Julie, Simon, Marc, Gonzalez, Hugo, Bouabdallah, Reda, Fitoussi, Olivier, Sebban, Catherine, López-Guillermo, Armando, Sanhes, Laurence, Morschhauser, Franck, Trotman, Judith, Corront, Bernadette, Choufi, Bachra, Snauwaert, Sylvia, Godmer, Pascal, Briere, Josette, Salles, Gilles, Gaulard, Philippe, Meignan, Michel, and Thieblemont, Catherine
- Abstract
Early identification of ultra-risk diffuse large B-cell lymphoma (DLBCL) patients is needed to aid stratification to innovative treatment. Previous studies suggested high baseline total metabolic tumor volume (TMTV) negatively impacts survival of DLBCL patients. We analyzed the prognostic impact of TMTV and prognostic indices in DLBCL patients, aged 60 to 80 years, from the phase 3 REMARC study that randomized responding patients to R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) into maintenance lenalidomide or placebo. TMTV was computed on baseline positron emission tomography/computed tomography using the 41% maximum standardized uptake value method; the optimal TMTV cutoff for progression-free (PFS) and overall survival (OS) was determined and confirmed by a training validation method. There were 301 out of 650 evaluable patients, including 192 patients classified as germinal center B-cell–like (GCB)/non-GCB and MYC/BCL2 expressor. Median baseline TMTV was 238 cm3; optimal TMTV cutoff was 220 cm3. Patients with high vs low TMTV showed worse/higher Eastern Cooperative Oncology Group performance status (ECOG PS) ≥2, stage III or IV disease, >1 extranodal site, elevated lactate dehydrogenase, International Prognostic Index (IPI) 3-5, and age-adjusted IPI 2-3. High vs low TMTV significantly impacted PFS and OS, independent of maintenance treatment. Although the GCB/non-GCB profile and MYC expression did not correlate with TMTV/survival, BCL2 >70% impacted PFS and could be stratified by TMTV. Multivariate analysis identified baseline TMTV and ECOG PS as independently associated with PFS and OS. Even in responding patients, after R-CHOP, high baseline TMTV was a strong prognosticator of inferior PFS and OS. Moreover, TMTV combined with ECOG PS may identify an ultra-risk DLBCL population. This trial was registered at www.clinicaltrials.gov as #NCT01122472.
- Published
- 2020
- Full Text
- View/download PDF
7. High total metabolic tumor volume at baseline predicts survival independent of response to therapy
- Author
-
Vercellino, Laetitia, Cottereau, Anne-Segolene, Casasnovas, Olivier, Tilly, Hervé, Feugier, Pierre, Chartier, Loic, Fruchart, Christophe, Roulin, Louise, Oberic, Lucie, Pica, Gian Matteo, Ribrag, Vincent, Abraham, Julie, Simon, Marc, Gonzalez, Hugo, Bouabdallah, Reda, Fitoussi, Olivier, Sebban, Catherine, López-Guillermo, Armando, Sanhes, Laurence, Morschhauser, Franck, Trotman, Judith, Corront, Bernadette, Choufi, Bachra, Snauwaert, Sylvia, Godmer, Pascal, Briere, Josette, Salles, Gilles, Gaulard, Philippe, Meignan, Michel, and Thieblemont, Catherine
- Abstract
Early identification of ultra-risk diffuse large B-cell lymphoma (DLBCL) patients is needed to aid stratification to innovative treatment. Previous studies suggested high baseline total metabolic tumor volume (TMTV) negatively impacts survival of DLBCL patients. We analyzed the prognostic impact of TMTV and prognostic indices in DLBCL patients, aged 60 to 80 years, from the phase 3 REMARC study that randomized responding patients to R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) into maintenance lenalidomide or placebo. TMTV was computed on baseline positron emission tomography/computed tomography using the 41% maximum standardized uptake value method; the optimal TMTV cutoff for progression-free (PFS) and overall survival (OS) was determined and confirmed by a training validation method. There were 301 out of 650 evaluable patients, including 192 patients classified as germinal center B-cell–like (GCB)/non-GCB and MYC/BCL2 expressor. Median baseline TMTV was 238 cm3; optimal TMTV cutoff was 220 cm3. Patients with high vs low TMTV showed worse/higher Eastern Cooperative Oncology Group performance status (ECOG PS) ≥2, stage III or IV disease, >1 extranodal site, elevated lactate dehydrogenase, International Prognostic Index (IPI) 3-5, and age-adjusted IPI 2-3. High vs low TMTV significantly impacted PFS and OS, independent of maintenance treatment. Although the GCB/non-GCB profile and MYC expression did not correlate with TMTV/survival, BCL2 >70% impacted PFS and could be stratified by TMTV. Multivariate analysis identified baseline TMTV and ECOG PS as independently associated with PFS and OS. Even in responding patients, after R-CHOP, high baseline TMTV was a strong prognosticator of inferior PFS and OS. Moreover, TMTV combined with ECOG PS may identify an ultra-risk DLBCL population. This trial was registered at www.clinicaltrials.govas #NCT01122472.
- Published
- 2020
- Full Text
- View/download PDF
8. Follicular lymphoma comprises germinal center–like and memory-like molecular subtypes with prognostic significance
- Author
-
Laurent, Camille, Trisal, Preeti, Tesson, Bruno, Seth, Sahil, Beyou, Alicia, Roulland, Sandrine, Lesne, Bastien, Van Acker, Nathalie, Cerapio, Juan-Pablo, Chartier, Loic, Guille, Arnaud, Stokes, Matthew E., Huang, C. Chris, Huet, Sarah, Gandhi, Anita K., Morschhauser, Franck, and Xerri, Luc
- Abstract
•RNA sequencing identified MEM- and GC-like FL subtypes related to the cell of origin and associated with specific mutational profiles and clinical outcomes.•IHC can be used routinely to identify patients with MEM-like FL with adverse PFS who can benefit from treatments other than R-chemotherapy.
- Published
- 2024
- Full Text
- View/download PDF
9. First Line Therapy Evaluation Using Propensity Score Approach in Newly Diagnosed Advanced Classical Hodgkin Lymphoma Patients from Prospective Real-World Realysa Cohort and Phase 3 AHL2011 Trial
- Author
-
Rossi, Cedric, Marouf, Amira, Deau Fischer, Benedicte, Cherblanc, Fanny, Cugnod, Emeline, Chartier, Loic, Fornecker, Luc Matthieu, Andre, Marc, Casasnovas, Rene-Olivier, and Ghesquieres, Herve
- Abstract
Background: AHL2011, a randomized phase III trial demonstrated that PET-CT after two cycles of BEACOPP escalatedchemotherapy safely guided treatment of patients aged 16-60 years with newly diagnosed advanced classical Hodgkin lymphoma (cHL) and allowed the use of ABVD in early responders with reduced toxicities and no impaired disease control. REALYSA study, a real-life multicentric cohort set up in France since 2018, included 6000 newly diagnosed lymphoma patients with over 1000 cHL patients. In the present study, we investigated whether real-world data could reproduce results issued from a randomized phase III clinical trial using the propensity score approach.
- Published
- 2023
- Full Text
- View/download PDF
10. Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial
- Author
-
Cottereau, Anne-Ségolène, Versari, Annibale, Loft, Annika, Casasnovas, Olivier, Bellei, Monica, Ricci, Romain, Bardet, Stéphane, Castagnoli, Antonio, Brice, Pauline, Raemaekers, John, Deau, Bénédicte, Fortpied, Catherine, Raveloarivahy, Tiana, Van Zele, Emelie, Chartier, Loic, Vander Borght, Thierry, Federico, Massimo, Hutchings, Martin, Ricardi, Umberto, Andre, Marc, and Meignan, Michel
- Abstract
We tested baseline positron emission tomography (PET)/computed tomography (CT) as a measure of total tumor burden to better identify high-risk patients with early-stage Hodgkin lymphoma (HL). Patients with stage I-II HL enrolled in the standard arm (combined modality treatment) of the H10 trial (NCT00433433) with available baseline PET and interim PET (iPET2) after 2 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine were included. Total metabolic tumor volume (TMTV) was measured on baseline PET. iPET2 findings were reported negative (DS1-3) or positive (DS4-5) with the Deauville scale (DS). The prognostic value of TMTV was evaluated and compared with baseline characteristics, staging classifications, and iPET2. A total of 258 patients were eligible: 101 favorable and 157 unfavorable. The median follow-up was 55 months, with 27 progression-free survival (PFS) and 12 overall survival (OS) events. TMTV was a prognosticator of PFS (P < .0001) and OS (P = .0001), with 86% and 84% specificity, respectively. Five-year PFS and OS were 71% and 83% in the high-TMTV (>147 cm3) group (n = 46), respectively, vs 92% and 98% in the low-TMTV group (≤147 cm3). In multivariable analysis including iPET2, TMTV was the only baseline prognosticator compared with the current staging systems proposed by the European Organization for Research and Treatment of Cancer/Groupe d’Etude des Lymphomes de l’Adulte, German Hodgkin Study Group, or National Comprehensive Cancer Network. TMTV and iPET2 were independently prognostic and, combined, identified 4 risk groups: low (TMTV≤147+DS1-3; 5-year PFS, 95%), low-intermediate (TMTV>147+DS1-3; 5-year PFS, 81.6%), high-intermediate (TMTV≤147+DS4-5; 5-year PFS, 50%), and high (TMTV>147+DS4-5; 5-year PFS, 25%). TMTV improves baseline risk stratification of patients with early-stage HL compared with current staging systems and the predictive value of early PET response as well.
- Published
- 2018
- Full Text
- View/download PDF
11. Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial
- Author
-
Cottereau, Anne-Ségolène, Versari, Annibale, Loft, Annika, Casasnovas, Olivier, Bellei, Monica, Ricci, Romain, Bardet, Stéphane, Castagnoli, Antonio, Brice, Pauline, Raemaekers, John, Deau, Bénédicte, Fortpied, Catherine, Raveloarivahy, Tiana, Van Zele, Emelie, Chartier, Loic, Vander Borght, Thierry, Federico, Massimo, Hutchings, Martin, Ricardi, Umberto, Andre, Marc, and Meignan, Michel
- Abstract
We tested baseline positron emission tomography (PET)/computed tomography (CT) as a measure of total tumor burden to better identify high-risk patients with early-stage Hodgkin lymphoma (HL). Patients with stage I-II HL enrolled in the standard arm (combined modality treatment) of the H10 trial (NCT00433433) with available baseline PET and interim PET (iPET2) after 2 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine were included. Total metabolic tumor volume (TMTV) was measured on baseline PET. iPET2 findings were reported negative (DS1-3) or positive (DS4-5) with the Deauville scale (DS). The prognostic value of TMTV was evaluated and compared with baseline characteristics, staging classifications, and iPET2. A total of 258 patients were eligible: 101 favorable and 157 unfavorable. The median follow-up was 55 months, with 27 progression-free survival (PFS) and 12 overall survival (OS) events. TMTV was a prognosticator of PFS (P< .0001) and OS (P= .0001), with 86% and 84% specificity, respectively. Five-year PFS and OS were 71% and 83% in the high-TMTV (>147 cm3) group (n = 46), respectively, vs 92% and 98% in the low-TMTV group (≤147 cm3). In multivariable analysis including iPET2, TMTV was the only baseline prognosticator compared with the current staging systems proposed by the European Organization for Research and Treatment of Cancer/Groupe d'Etude des Lymphomes de l'Adulte, German Hodgkin Study Group, or National Comprehensive Cancer Network. TMTV and iPET2 were independently prognostic and, combined, identified 4 risk groups: low (TMTV≤147+DS1-3; 5-year PFS, 95%), low-intermediate (TMTV>147+DS1-3; 5-year PFS, 81.6%), high-intermediate (TMTV≤147+DS4-5; 5-year PFS, 50%), and high (TMTV>147+DS4-5; 5-year PFS, 25%). TMTV improves baseline risk stratification of patients with early-stage HL compared with current staging systems and the predictive value of early PET response as well.
- Published
- 2018
- Full Text
- View/download PDF
12. Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA group
- Author
-
Aubrais, Raphaelle, Bouabdallah, Krimo, Chartier, Loic, Herbaux, Charles, Banos, Anne, Brice, Pauline, Sibon, David, Schiano, Jean Marc, Cluzeau, Thomas, Laribi, Kamel, Le Calloch, Ronan, Bellal, Mathieu, Delapierre, Baptiste, Daguindau, Nicolas, Amorim, Sandy, Agbetiafa, Kossi, Chauchet, Adrien, Besson, Caroline, Durot, Eric, Bonnet, Christophe, Fouillet, Ludovic, Bijou, Fontanet, Tournilhac, Olivier, Gaulard, Philippe, Parrens, Marie-Cécile, and Damaj, Gandhi
- Abstract
•Brentuximab-vedotin in combination with bendamustine is highly active salvage therapy in R/R PTCL with an ORR of 68% and CR of 49%.•Patients who underwent an allo-stem cell transplantation in CR had better outcome. m-PFS and OS was 19.3 months and not reached.
- Published
- 2023
- Full Text
- View/download PDF
13. Hepatitis B Virus Exposure During Childhood in Cameroon, Central African Republic and Senegal After the Integration of HBV Vaccine in the Expanded Program on Immunization
- Author
-
Rey-Cuille, Marie-Anne, Njouom, Richard, Bekondi, Claudine, Seck, Abdoulaye, Gody, Chrysostome, Bata, Petulla, Garin, Benoit, Maylin, Sarah, Chartier, Loic, Simon, François, and Vray, Muriel
- Abstract
More than 2 billion people worldwide have been exposed to hepatitis B virus (HBV). To prevent these infections, Senegal and Cameroon integrated the HBV vaccine into their Expanded Program on Immunization (EPI) in 2005, as did the Central African Republic (CAR) in 2008. We evaluated the prevalence of HBV exposure and infection after the integration of the HBV vaccine in the EPI.
- Published
- 2013
- Full Text
- View/download PDF
14. Characterisation of 3D printers using fibre Bragg gratings
- Author
-
Chung, Youngjoo, Jin, Wei, Lee, Byoungho, Canning, John, Nakamura, Kentaro, Yuan, Libo, Canning, John, Cook, Kevin, Hossain, Md. Arafat, Han, Chunyang, Chartier, Loic, and Athanaze, Tristan
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.